Clinical Trial Update: Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics, safety and tolerability study of a single 125 mg subcutaneous dose of abatacept in rheumatoid arthritis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Rheumatoid Arthritis (RA) | Phase 1 | Status: UNKNOWN